Agency: National Institute of Allergy and Infectious Diseases (NIAID)
Deadline: 9/1/97
Funding: No specific setaside. Refer to PA-96-068.
Contact:

Chris Lambros, 301-402-2304; email: chris_lambros@nih.gov;

NIAID is looking for research that emphasizes underexploited facets of the basic biology, biochemistry, and pathophysiology of certain HIV-related opportunistic pathogens.

HIV-1 Infection of the Central Nervous System

Agencies: National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Drug Abuse (NIDA), and National Institute of Child Health and Human Development (NICHD)
Deadline: 9/1/97
Funding: No specific setaside. Refer to PA-97-017.
Contact:

Walter Goldschmidts, NIMH, 301-443-7281, email: goldsch@nih.gov;
A. P. Kerza-Kwiatecki, NINDS, 301-496-1431, email: ak45w@nih.gov;
Lynda Erinoff, NIDA, 301-443-6046, email: ak45w@nih.gov
Anne Willoughby, NICHD, 301-496-7339, email: willouga@hd01.nichd.nih.gov

NIMH, NINDS, NIDA, and NICHD seek applications to support research on the pathogenic mechanisms involved in HIV-1associated neurobehavioral and neurological dysfunction in adults and children.

HIV: Viral Load in Brain and Neurobehavioral Correlates

Agencies: NIMH and NINDS
Deadline: 9/1/97
Funding: No specific setaside. Refer to PA-96-059.
Contact:

Dianne Rausch, NIMH, 301-443-6100, email: dr89b@nih.gov
A. P. Kerza-Kwiatecki, NINDS, 301-496-1431, email: ak45w@nih.gov

NIMH and NINDS seek research applications to identify ways to quantitate viral load within the central nervous system (CNS); correlate the quantity of virus within the CNS with neurobehavioral and neurological changes; detect alterations in neuronal function due to the presence of virus; and distinguish and test drugs that prevent or reverse neuronal dysfunction.

Mechanisms of AIDS Pathogenesis

Agencies: NIAID and National Institute of Dental Research (NIDR)
Deadline: 9/1/97
Funding: No specific setaside. Refer to PA-96-072.
Contact:

Opendra Sharma, NIAID, 301-496-9041, email: os4g@nih.gov
Eleni Kousvelari, NIDR, 301-594-2427, email: kousvelari@de45.nidr.nih.gov

NIAID and NIDR seek grant applications for research on HIV pathogenesis that will tie in vitro studies to studies of human clinical or epidemiologic cohorts, animal models, or appropriate specimens from humans or animals.

Novel HIV Vaccine Design

Agency: NIAID
Deadline: 9/1/97
Funding: No specific setaside. Refer to PA-96-078.
Contact:

Frederick Vogel, 301-402-0121, email: fv1v@nih.gov

NIAID solicits investigator-initiated research to study novel high risk, high impact HIV vaccine concepts in early stages of development. Vaccine concepts currently being tested in primate models or clinical trials are not eligible.

Research on the Hematologic Abnormalities in AIDS

Agencies: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and National Heart, Lung, and Blood Institute (NHLBI)
Deadline: 9/1/97
Funding: No specific setaside. Refer to PA-96-066.
Contact:

Ralph Bain, NIDDK, 301-594-7717, email: Ralph_Bain@nih.gov
Helena Mishoe, NHLBI, 301-435-0050, email: hm31y@nih.gov

NIDDK and NHLBI invite research focusing on the cellular basis of hematologic abnormalities exhibited by HIV-infected humans.

Drug Use, Sexual Risk Behaviors, and HIV in Men

Agency: NIDA
Deadline: 9/1/97
Funding: No specific setaside. Refer to PA-96-074.
Contact:

Richard Needle, 301-443-6720, email: RN28E@nih.gov
Elizabeth Lambert, email: EL46I@nih.gov
Helen Cesari, email: HC30X@nih.gov

NIDA seeks research on HIV risk behaviors among drug-using men who have sex with men (DU MSM) and adverse health consequences; HIV prevention interventions for DU MSM; and new behavioral therapies, drug abuse treatments, and health care services delivery to DU MSM.

HIV, AIDS, and Related Illnesses Collaboration Award

Agency: Fogarty International Center
Deadline: 9/1/97
Funding: Up to $20,000 per year; up to 3 years. Refer to PAR-97-033.
Contact:

Jean Flagg-Newton, 301-496-1653, email: flaggnej@ficod.fic.nih.gov

Individual research grants for U.S. investigators and foreign collaborators to conduct research in any country, mainly at the foreign site.

Behavioral Science Track Awards for Rapid Transition

Agency: NIDA
Deadline: 9/1/97
Funding: No specific setaside. Refer to PAR-97-046.
Contact:

NIDA, Division of Basic Research, 301-443-6300;
NIDA, Division of Clinical and Services Research, 301-443-6697;
NIDA, Division of Epidemiology and Prevention Research, 301-443-6504

Applications are sought to study behavioral--neurocognitive, cognitive, motivational, social, and community--factors in drug abuse. Studies examining the role that drug abuse plays in HIV transmission are especially welcome.